• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

结核分枝杆菌 KasA 的分子动力学:对抑制剂和底物结合的影响及其对药物设计的意义。

Molecular dynamics of Mycobacterium tuberculosis KasA: implications for inhibitor and substrate binding and consequences for drug design.

机构信息

Institute of Pharmacy and Food Chemistry, University of Würzburg, 97074, Würzburg, Germany.

出版信息

J Comput Aided Mol Des. 2011 Nov;25(11):1053-69. doi: 10.1007/s10822-011-9483-4. Epub 2011 Nov 11.

DOI:10.1007/s10822-011-9483-4
PMID:22076471
Abstract

Inhibition of the production of fatty acids as essential components of the mycobacterial cell wall has been an established way of fighting tuberculosis for decades. However, increasing resistances and an outdated medical treatment call for the validation of new targets involved in this crucial pathway. In this regard, the β-ketoacyl ACP synthase KasA is a promising enzyme. In this study, three molecular dynamics simulations based on the wildtype crystal structures of inhibitor bound and unbound KasA were performed in order to investigate the flexibility and conformational space of this target. We present an exhaustive analysis of the binding-site flexibility and representative pocket conformations that may serve as new starting points for structure-based drug design. We also revealed a mechanism which may account for the comparatively low binding affinity of thiolactomycin. Furthermore, we examined the behavior of water molecules within the binding pocket and provide recommendations how to handle them in the drug design process. Finally, we analyzed the dynamics of a channel that accommodates the long-chain fatty acid substrates and, thereby, propose a mechanism of substrate access to this channel and how products are most likely released.

摘要

几十年来,抑制分枝杆菌细胞壁必需成分脂肪酸的产生一直是治疗结核病的一种既定方法。然而,不断增加的耐药性和过时的医疗方法需要验证新的靶点,这些靶点涉及到这个关键途径。在这方面,β-酮酰基 ACP 合酶 KasA 是一种很有前途的酶。在这项研究中,我们基于抑制剂结合和未结合的 KasA 的野生型晶体结构进行了三次分子动力学模拟,以研究该靶标的柔韧性和构象空间。我们对结合位点的柔韧性和代表性口袋构象进行了详尽的分析,这些构象可能成为基于结构的药物设计的新起点。我们还揭示了一种可能解释硫乳霉素结合亲和力相对较低的机制。此外,我们研究了结合口袋内水分子的行为,并提供了在药物设计过程中处理这些水分子的建议。最后,我们分析了容纳长链脂肪酸底物的通道的动力学,并提出了一种底物进入该通道的机制,以及产物最有可能释放的方式。

相似文献

1
Molecular dynamics of Mycobacterium tuberculosis KasA: implications for inhibitor and substrate binding and consequences for drug design.结核分枝杆菌 KasA 的分子动力学:对抑制剂和底物结合的影响及其对药物设计的意义。
J Comput Aided Mol Des. 2011 Nov;25(11):1053-69. doi: 10.1007/s10822-011-9483-4. Epub 2011 Nov 11.
2
In Silico Drug Design of Thiolactomycin Derivatives Against Mtb-KasA Enzyme to Inhibit Multidrug Resistance of Mycobacterium tuberculosis.基于 Mtb-KasA 酶的硫霉素衍生物的计算机药物设计以抑制结核分枝杆菌的多药耐药性。
Interdiscip Sci. 2019 Jun;11(2):215-225. doi: 10.1007/s12539-017-0257-0. Epub 2017 Aug 30.
3
Purification and biochemical characterization of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthases KasA and KasB.结核分枝杆菌β-酮酰-酰基载体蛋白合成酶KasA和KasB的纯化及生化特性分析
J Biol Chem. 2001 Dec 14;276(50):47029-37. doi: 10.1074/jbc.M108903200. Epub 2001 Oct 12.
4
Mechanistic Insight into how β-Ketoacyl ACP Synthase I (KasA) Recognizes the Fatty Acid Chain Length of its Substrate.β-酮酰基 ACP 合酶 I(KasA)识别其底物脂肪酸链长的机制见解。
Chempluschem. 2024 Jul;89(7):e202300568. doi: 10.1002/cplu.202300568. Epub 2023 Dec 11.
5
Substrate recognition by β-ketoacyl-ACP synthases.β-酮酰基-ACP 合酶对底物的识别。
Biochemistry. 2011 Dec 13;50(49):10678-86. doi: 10.1021/bi201199x. Epub 2011 Nov 17.
6
Crystal structures of Mycobacterium tuberculosis KasA show mode of action within cell wall biosynthesis and its inhibition by thiolactomycin.结核分枝杆菌KasA的晶体结构显示其在细胞壁生物合成中的作用模式及其被硫内酯霉素抑制的情况。
Structure. 2009 Jul 15;17(7):1004-13. doi: 10.1016/j.str.2009.04.012.
7
A Preclinical Candidate Targeting Mycobacterium tuberculosis KasA.一种靶向结核分枝杆菌KasA的临床前候选药物。
Cell Chem Biol. 2020 May 21;27(5):560-570.e10. doi: 10.1016/j.chembiol.2020.02.007. Epub 2020 Mar 19.
8
Synergistic Lethality of a Binary Inhibitor of Mycobacterium tuberculosis KasA.结核分枝杆菌 KasA 的双抑制剂的协同致死性。
mBio. 2018 Dec 18;9(6):e02101-17. doi: 10.1128/mBio.02101-17.
9
Elucidation of the protonation states of the catalytic residues in mtKasA: implications for inhibitor design.阐明 mtKasA 中催化残基的质子化状态:对抑制剂设计的启示。
Biochemistry. 2011 Jun 28;50(25):5743-56. doi: 10.1021/bi200006t. Epub 2011 Jun 7.
10
Structural insight into conformational dynamics of non-active site mutations in KasA: A Mycobacterium tuberculosis target protein.结构洞察非活性位点突变在 KasA 中的构象动力学:结核分枝杆菌靶蛋白。
Gene. 2019 Dec 15;720:144082. doi: 10.1016/j.gene.2019.144082. Epub 2019 Aug 30.

引用本文的文献

1
Anti-Tubercular Properties of 4-Amino-5-(4-Fluoro-3- Phenoxyphenyl)-4-1,2,4-Triazole-3-Thiol and Its Schiff Bases: Computational Input and Molecular Dynamics.4-氨基-5-(4-氟-3-苯氧基苯基)-4H-1,2,4-三唑-3-硫醇及其席夫碱的抗结核特性:计算输入与分子动力学
Antibiotics (Basel). 2020 Aug 31;9(9):559. doi: 10.3390/antibiotics9090559.
2
Design, Synthesis and Biological Evaluation of Some Triazole Schiff's Base Derivatives as Potential Antitubercular Agents.一些三唑席夫碱衍生物作为潜在抗结核药物的设计、合成及生物学评价
Open Med Chem J. 2018 Apr 30;12:48-59. doi: 10.2174/1874104501812010048. eCollection 2018.
3

本文引用的文献

1
Elucidation of the protonation states of the catalytic residues in mtKasA: implications for inhibitor design.阐明 mtKasA 中催化残基的质子化状态:对抑制剂设计的启示。
Biochemistry. 2011 Jun 28;50(25):5743-56. doi: 10.1021/bi200006t. Epub 2011 Jun 7.
2
The challenge of new drug discovery for tuberculosis.结核病新药研发面临的挑战。
Nature. 2011 Jan 27;469(7331):483-90. doi: 10.1038/nature09657.
3
The population dynamics and control of tuberculosis.结核病的种群动态与控制。
Conformational flexibility of DENV NS2B/NS3pro: from the inhibitor effect to the serotype influence.
登革病毒NS2B/NS3蛋白酶的构象灵活性:从抑制剂作用到血清型影响
J Comput Aided Mol Des. 2016 Mar;30(3):251-70. doi: 10.1007/s10822-016-9901-8. Epub 2016 Feb 29.
4
Structural basis for the recognition of mycolic acid precursors by KasA, a condensing enzyme and drug target from Mycobacterium tuberculosis.结核分枝杆菌缩合酶和药物靶标 KasA 识别新型分枝菌酸前体的结构基础
J Biol Chem. 2013 Nov 22;288(47):34190-34204. doi: 10.1074/jbc.M113.511436. Epub 2013 Oct 9.
Science. 2010 May 14;328(5980):856-61. doi: 10.1126/science.1185449.
4
Slow onset inhibition of bacterial beta-ketoacyl-acyl carrier protein synthases by thiolactomycin.硫乳霉素对细菌β-酮酰基-酰基辅酶 A 合成酶的缓慢起始抑制作用。
J Biol Chem. 2010 Feb 26;285(9):6161-9. doi: 10.1074/jbc.M109.077909. Epub 2009 Dec 16.
5
Crystal structures of Mycobacterium tuberculosis KasA show mode of action within cell wall biosynthesis and its inhibition by thiolactomycin.结核分枝杆菌KasA的晶体结构显示其在细胞壁生物合成中的作用模式及其被硫内酯霉素抑制的情况。
Structure. 2009 Jul 15;17(7):1004-13. doi: 10.1016/j.str.2009.04.012.
6
The mechanism of isoniazid killing: clarity through the scope of genetics.异烟肼杀菌机制:通过遗传学范畴得以明晰。
Annu Rev Microbiol. 2007;61:35-50. doi: 10.1146/annurev.micro.61.111606.122346.
7
Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides.芳基酰胺对结核分枝杆菌烯酰基酰基载体蛋白还原酶InhA的抑制作用。
Bioorg Med Chem. 2007 Nov 1;15(21):6649-58. doi: 10.1016/j.bmc.2007.08.013. Epub 2007 Aug 15.
8
Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis.吡咯烷羧酰胺作为一类新型的结核分枝杆菌烯酰酰基载体蛋白还原酶抑制剂。
J Med Chem. 2006 Oct 19;49(21):6308-23. doi: 10.1021/jm060715y.
9
Platensimycin is a selective FabF inhibitor with potent antibiotic properties.普拉特链霉菌素是一种具有强效抗菌特性的选择性FabF抑制剂。
Nature. 2006 May 18;441(7091):358-61. doi: 10.1038/nature04784.
10
Automatic atom type and bond type perception in molecular mechanical calculations.分子力学计算中的自动原子类型和键类型识别
J Mol Graph Model. 2006 Oct;25(2):247-60. doi: 10.1016/j.jmgm.2005.12.005. Epub 2006 Feb 3.